PURPOSE: A composition for treating Epstein-Barr virus-positive gastric cancer is provided to suppress proliferation of Epstein-Barr virus and to effectively treat Epstein-Barr virus-positive gastric cancer when ganciclovir and gemcitabine are combined. CONSTITUTION: A pharmaceutical composition for treating Epstein-Barr virus-positive gastric cancer contains an anti-herpes viral agent and 1 ng/ml or greater of gemcitabine. The anti-herpes viral agent is selected among ganciclovir acyclovir penc...

PURPOSE: A new extravascular leak blocker is provided to heal or prevent diseases caused by an extravascular leak caused by damage to the integrity of blood vessels. CONSTITUTION: A pharmaceutical composite (a) for healing and preventing an extravascular leak includes a pharmaceutical effective amount (b) of a ginsenoside Rk1 analogue and pharmaceutically permitted infections. The extravascular leak diseases is diabetes inflammation retinopathy diabetic retinopathy macular degeneration glaucoma ...

PURPOSE: A pharmaceutical composition for treating lupus nephritis including thalidomide or lenalidomide is provided to prevent lupus nephritis by reducing the amount of proteinuria in a lupus nephritis animal model. CONSTITUTION: A pharmaceutical composition for treating lupus nephritis including thalidomide or lenalidomide comprises a thalidomide or a lenalidomide. The pharmaceutical composition additionally includes a corticosteroid The pharmaceutical composition additionally includes at leas...

The present invention relates to a pharmaceutical composition comprising thalidomide or lenalidomide for coadministration for preventing or treating adrenal disorders. The amount of albuminuria is significantly reduced in a lupus nephritis animal model by using the pharmaceutical composition for preventing and treating adrenal disorders according to the present invention and thus the composition of the present invention exhibits an effect for treating and preventing lupus nephritis.

PURPOSE: A composition containing multifunctional nanoparticles for rheumatoid arthritis is provided to control drug release rate by regulating decomposition rate of biodegradable nanoparticles and to remove non-invasive synovial membrane. CONSTITUTION: A composition for treating rheumatoid arthritis contains a multifunctional nanoparticle. The multifunctional nanoparticle comprises: a polymer nanoparticle containing an antirheumatic drug; a magnetic material thin film which is partially deposit...

PURPOSE: A pharmaceutical composition containing a thiazolidinedione-based drug for preventing and treating Alzheimer's disease is provided to enhance LRP1 expression and the discharge of beta-amyloid into the blood. CONSTITUTION: A pharmaceutical composition for treating neurological disorders contains a thiazolidinedione-based drug as an active ingredient. The thiazolidinedione-based drug includes rosiglitazone pioglitazone or troglitazone. The pharmaceutical composition enhances the LRP1 expr...

PURPOSE: A nanofiber support of core-shell and a method for manufacturing the same are provided to continuously release medicine by adhering on a lesion. CONSTITUTION: A nanofiber support of core-shell forms contains: a core containing biocompatible natural polymers and medicine and a shell of biocompatible hydrophobic synthetic polymers. The biocompatible natural polymers are alginate chitosan collagen or gelatin. The biocompatible hydrophobic synthetic polymers are polycaprolactone polylactic ...

PURPOSE: A medicinal composition for anti-fungi contains an inhibitor of Cryptococcus neoformans protein or gene encoding the protein is provided to reduce use and to enhance efficiency. CONSTITUTION: An antifungal medicinal composition contains an inhibitor of Ras1 Ras2 Cdc24 Gpa1 Cac1 Aca1 Pka1 Hsp12 or Hsp122 of Cryptococcus neoformans. The inhibitor is an inhibitor of Cac1 or Pka1. The antifungal medicinal composition contains an inhibitor is administered with polyenes or azolic antifungal a...

PURPOSE: A composition containing a compound with piperazine imino structure for suppressing angiogenesis is provided to prevent apoptosis induction of endothelial cells and to suppress angiogenic response. CONSTITUTION: A pharmaceutical composition for suppressing angiogenesis contains pharmaceutically active amount of compound of chemical formula 1. In chemical formula 1 R1-R5 are independently hydrogen halo hydroxy C1-C12 alkyl or C1-C6 alkoxy; R1-R4 and R7-R9 are independently hydrogen or C1...

PURPOSE: An inhibitor to protein or gene of Cryptococcus neoformans is provided to use as a complex therapeutic agent which enhances fungus-killing effect. CONSTITUTION: An antifungal pharmaceutical composition contains SSK1 TCO2 SSK2 PBS2 or HOG1 of Cryptococcus neoformans. The pharmaceutical composition is gradually or simultaneously administered with ergosterol-binding angifungal agent. The ergosterol antifungal agent is a polyene antifungal agent. The polyene antifungal agent is natamycin ri...